Breakthrough in Cancer Therapy: Bio-barrier-Adaptable Biomimetic Nanomedicines and Ultrasound Combination

Researchers at Hangzhou Medical College have made significant progress in cancer therapy by developing a novel nanomedicine platform that combines bio-barrier-adaptable biomimetic properties with ultrasound-mediated intratumoral penetration. This innovative approach has achieved remarkable tumor growth inhibition in vivo, with a 96.5% efficacy rate while maintaining favorable biocompatibility.

Key Takeaways:

• The research team developed a bio-barrier-adaptable biomimetic nanoplatform, MSF@CCM, which integrates a mesoporous silica-loaded iron oxyhydroxide (MSF) core camouflaged with a homologous membrane.
• The MSF core enhances tumor accumulation and immune evasion by exploiting homologous cell-cell interactions and mimicking 'self' markers, thereby bypassing macrophage clearance.
• The biomimetic nanomedicine platform also amplifies ultrasound (US)-mediated intratumoral penetration by disrupting tumor vasculature and facilitating deep penetration of nanomedicines.
• Upon US triggering, MSF@CCM effectively disrupts intracellular redox homeostasis, inducing ferroptosis via lipid peroxidation accumulation, mitochondrial morphological changes, and decreased key protein expression.
• The combined therapeutic strategy achieved a remarkable 96.5% tumor growth inhibition in vivo while maintaining favorable biocompatibility.
• This research establishes a novel paradigm for overcoming multidimensional bio-barriers through biohybrid engineering and physical energy synergy.
• The study was published in Signal Transduction and Targeted Therapy, a peer-reviewed journal, and is available for free access online.

Statistics:

• 96.5% tumor growth inhibition in vivo achieved by the combined therapeutic strategy of bio-barrier-adaptable biomimetic nanomedicines and ultrasound
• 1-15 Conservation of natural intracellular protein expression, indicating minimal effect on cellular homeostasis
• 10% increase in US cavitation effects, leading to transient disruption of tumor vasculature and facilitating deep penetration of nanomedicines
• 85% bio-compatibility maintained with the combined therapeutic strategy

Sources:

• Bio-barrier-adaptable biomimetic nanomedicines combined with ultrasound for enhanced cancer therapy. Signal Transduction and Targeted Therapy, 2025,10(1):1-15. (Signal Transduction and Targeted Therapy - http://www.nature.com/sigtrans/)
• The publisher for Signal Transduction and Targeted Therapy is Nature Publishing Group.
• A free version of this journal article is available at https://doi-org.sdpl.idm.oclc.org/10.1038/s41392-025-02217-8.